Table 1.

Current trials involving treatment of rheumatoid arthritis and interstitial lung disease

Name/NCT	Drug	Design	Primary outcome	Status
APRIL NCT 03084419	Abatacept	Open Label	Change in FVC at 24 months	Recruiting
TRAIL 1 NCT02808871	Pirfenidone (phase 2 study)	Randomized double blind placebo control	Progression-free survival over 52 weeks	Recruiting
PULMORA NCT04311567	Tofacitinib vs. methotrexate	Open label	Change in total ILD score by HRCT at 24 weeks	Recruiting
NCT04928586 (New)	DMARDS and pirfenidonea	Prospective cohort study	Change in FVC and DCLO in 12 months	Recruiting

^aIn CTD-ILD, including RA-ILD